HCW Biologics (HCWB) Q3 2025 earnings summary

Executive summary

• Net loss for Q3 2025 was $4.6M, with a nine-month net loss of $8.7M, reflecting ongoing R&D and administrative expenses as the company advances its immunotherapy pipeline and navigates significant legal and financing events.

• Revenue for Q3 2025 dropped to $15.6K from $426K in Q3 2024 due to the suspension of the Wugen License, with only ancillary service revenue recognized.

• The company executed a $7.7M debt restructuring, raised $7.0M in equity, and remains non-compliant with Nasdaq’s minimum equity rule but received an extension to regain compliance by December 31, 2025.

• Legal settlements resolved major uncertainties, but $12.1M in legal fees remain unpaid, and the company faces ongoing litigation and construction-related disputes.

• Initiated search for a commercial partner for T-cell engager compounds and opened two clinical sites for a Phase 1 trial of HCW9302 in alopecia areata, with first patient dosing expected in Q4 2025.

Financial highlights

• Q3 2025 net loss: $4.6M; nine-month net loss: $8.7M, a significant improvement from $26.7M loss in the prior year period, mainly due to lower legal expenses.

• Revenue for Q3 2025: $15.6K (down 96% YoY); nine months: $27.2K (down 99% YoY), reflecting the Wugen License suspension.

• R&D expenses for Q3 2025: $1.4M (up 18% YoY); nine months: $4.1M (down 23% YoY), with higher preclinical costs offset by lower manufacturing and clinical trial expenses.

• General and administrative expenses for Q3 2025: $1.9M (up 15% YoY); nine months: $6.2M (up 29% YoY), driven by higher salaries, professional services, and financing costs.

• Cash and equivalents at September 30, 2025: $1.1M, with substantial doubt about the ability to continue as a going concern without additional funding.

Outlook and guidance

• Management expects increased clinical expenses as the Phase 1 trial for HCW9302 in alopecia areata begins in Q4 2025.

• The company is actively seeking licensing partners for its TRBC platform molecules and additional equity financing to support operations.

• If unable to raise further capital, management may revise the business plan and reduce costs, with the risk of curtailing or ceasing operations.

• Nasdaq Hearings Panel granted continued listing, contingent on compliance with the $2.5M equity rule by December 31, 2025.

• Financing plan underway, but success with remaining steps is uncertain.